SARS-COV-2 NGS
Automated SARS-CoV 2 variant typing and reporting directly from NGS sequence data
Download PDF
From its origins in HIV drug-resistance testing, Hyrax has extended the Exatype genotyping platform to accommodate any disease or test. Our pipeline is currently being used to report drug resistance in HIV, as well as consensus sequences, mutations, and lineage and clade typing in SARS-CoV-2 (COVID-19).
Automated SARS-CoV 2 variant typing and reporting directly from NGS sequence data
Download PDF
Easy-to-use HIV Genotyping solution for NGS sequence data
Download PDF
Consolidated HIV Genotyping solution for sequencing done by capillary electrophoresis (CE), e.g. the Applied Biosystems 3730 and 3500 Series Genetic Analyzers.
Download PDF
Our proviral solution assists in the selection of drug regimens that are better-tolerated in treatment-experienced people.
Download PDF
Our modular platform can analyse and interpret sequence data from an ever-expanding range of applications, including:
Genotyping and drug-resistance testing in infectious diseases e.g. HIV, TB, SARS-CoV-2.
Multi-target diagnostics, e.g. infectious disease panels.
Tumour profiling and drug-susceptibility testing in cancer.
Low abundance variant detection e.g. detecting mixed infections or the detection of biomarkers in liquid biopsies.
